T cell Ig and mucin domain (TIM)-4 is preferentially expressed on antigen-presenting cells, and its counter-ligand, TIM-1, is thought to deliver co-stimulating signals to T cells. However, the physiological functions of TIM-4 remain unclear. Here, we demonstrate that TIM-4 inhibits naive T cell activation through a ligand other than TIM-1. The inhibitory effect of TIM-4 was specific to naive T cells which do not express TIM-1, and the effect disappeared in pre-activated T cells. Conversely, antibodymediated blockade of TIM-4 in vivo substantially suppressed T cell-mediated inflammatory responses despite enhanced generation of antigen-specific T cells. Furthermore, treatment with anti-TIM-4 reduced the inflammatory responses developed in mice that were adoptively transferred with antigenprimed T cells. These results suggest that TIM-4 exerts bimodal functions depending on the activation status of T cells.
Introduction
The T cell Ig and mucin domain (TIM) gene family members, identified within the T cell and airway phenotype regulator locus (1), have recently been described as molecules involved in immune responses (2, 3) . The TIM family consists of eight members in mice (encoding TIM-1 to TIM-4 and putative TIM-5 to TIM-8) and three members in humans (Tim-1, Tim-3 and Tim-4). In humans, hepatitis A virus cellular receptor (HAVcr-1, the homologue of mouse TIM-1) was identified as being important in asthma and atopy because of the association between the polymorphism of HAVcr-1 and the prevalence of atopic diseases (4) (5) (6) . TIM-1 is expressed on activated CD4
+ T cells during the development of T h , and its expression level is higher on differentiated T h 2 than on T h 1 (7) . TIM-1 has a tyrosine phosphorylation motif in its cytoplasmic tail and is reported to deliver co-stimulatory signals in T cells (8) . In addition, cross-linking of TIM-1 on activated CD4
+ T cells using anti-TIM-1 mAb enhances T cell proliferation as well as production of IL-4 and IFN-c (7) .
Recently, TIM-4 was identified as a natural ligand for TIM-1 (9) . Unlike other TIM family members, TIM-4 lacks a tyrosine phosphorylation motif in its intracellular domain. TIM-4 was initially reported as SMUCKLER [spleen, mucin-containing, knock-out of lymphotoxin (LT)], which is down-regulated in the spleens of LTa-or LTb-deficient mice (10) . TIM-4 mRNA expression was observed in peripheral lymphoid tissues, particularly within marginal zones of spleen and was relatively low in lymphoid cells. However, a recent report showed that TIM-4 mRNA is expressed in CD11b + and CD11c + antigen-presenting cells (APCs) but not in B cells or T cells (9) . Therefore, TIM-4-TIM-1 engagement might be involved in APC-T cell interaction to provide a co-stimulatory signal for T cell activation. The administration of soluble TIM-4 protein has been shown to induce hyper-proliferation of T cells in vivo (9) . However, the in vitro function of soluble TIM-4 is not exactly concordant; lower and higher concentrations of soluble TIM-4 inhibit and enhance T cell proliferation, respectively. These findings imply that the TIM-4-TIM-1 interaction is not mutually exclusive and that TIM-4 exhibits diverse functions rather than simply a co-stimulatory effect for T cell activation. Therefore, the precise function of TIM-4 remains unknown.
Here, we demonstrate that TIM-4 on APCs inhibits naive T cell proliferation through binding to a non-TIM-1 receptor. TIM-4 binds to naive CD4 + T cells which do not express TIM-1. Soluble TIM-4 proteins significantly decrease proliferation of naive CD4 + T cells stimulated by anti-CD3 and anti-CD28 in vitro. In addition, the high expression of TIM-4 on APCs results in reduced proliferation of antigen-specific naive T cells. The in vitro inhibitory activity of TIM-4 is not observed in pre-activated or antigen-experienced T cells. We also show that the blocking of TIM-4 by anti-TIM-4 antibody enhances antigen-specific naive T cell activation and in vivo T cell priming. However, in vivo administration of anti-TIM-4 affects the effector phase of cellular immune responses and leads to the amelioration of clinical symptoms. These results demonstrate that TIM-4 can exert diverse functions depending on the activation status of T cells, possibly by using distinct receptors.
Methods

Ig fusion proteins and transfectants
A truncated form of murine TIM-4 cDNA was prepared from full-length cDNA derived from splenocytes by PCR using a pair of oligonucleotide primers containing a sense sequence including a SalI site (5#-GACGTCGACGATCCTAT-CAAAATGTCCAAG-3#) and an anti-sense sequence including a BamHI site (5#-GACGGATCCTACTTACTTTGTCT-GCTGTTGATCTGATGTG-3#) for TIM-4-Fc. The resulting SalI-BamHI fragments were used to replace the SalI-BamHI DNA fragments of pEFBos human IgG1-Fc cassette to generate these proteins. Soluble proteins were produced using the Freestyle TM 293 Expression System, according to the manufacturer's protocols (Invitrogen, Carlsbad, CA, USA), and purified from culture supernatants using Protein ASepharose (GE Healthcare).
TIM-1-, TIM-2-, TIM-3-and TIM-4-expressing 2B4 cells were generated by retroviral vector-mediated gene introduction. Briefly, full-length TIM-1, TIM-2, TIM-3 and TIM-4 fragments were inserted into the EcoRI and the BamHI site of the pMX-IRES-GFP vectors and retroviruses were packaged using Plat-E cells. Viral supernatants were collected 48 h after transfection and cultured with 2B4 cells for 24 h. The sorting of green fluorescence protein (GFP)-positive cells by FACS was repeated three times for enrichment and purification. TIM-4 was correspondingly introduced into MHC class IIand CD80-expressing mouse fibroblast cells (IC187 cells).
Generation of mAbs
Female Lewis rats were immunized in the footpads with murine full-length TIM-4-Fc in CFA and boosted with 50 lg of TIM-4-Fc in PBS after 7 days. The next day, draining lymph node (LN) cells were fused with P3U1 cells and the hybridoma supernatants were screened by cell surface staining of mouse TIM-4-transfected 2B4 cells. Two anti-TIM-4-specific hybridomas were made and incubated in cultivation flasks (Integra Biosciences, Chur, Switzerland). After purification with Protein A-Sepharose, the antibodies were coupled to biotin. Anti-TIM-1 mAbs were generated by immunizing Fischer rats as described previously (11) .
Flow cytometric analysis and antibodies
Single-cell suspensions were prepared from mice spleens (8-12 weeks old). Cells were stained with the following antibodies: anti-CD4 (GK1.5), anti-CD8 (Ly-2), anti-B220 (RA3-6B2), anti-CD11b (M1/170), anti-CD11c (HL-3), anti-I-Ab (25-9-7), anti-CD62L (MEL-14), anti-MOMA-1 and anti-NK1.1, conjugated to FITC, PE, allophycocyanin or biotin in the presence of Fc block (anti-CD16/32, 2.4G2). Streptavidinallophycocyanin was used as the secondary reagent for biotinylated antibodies. These antibodies and reagents were purchased from BD PharMingen, and data analysis was performed using FlowJo software (Treestar, Ashland, OR, USA).
In vitro proliferation assays
CD4
+ CD62L + CD44 low naive T cells and CD11c + dendritic cells (DCs) were isolated from the spleen or LNs using flow cytometry (FACSAria, BD Biosciences) and MACS sorting (Miltenyi Biotec, Bergisch Gladbach, Germany), respectively. The resulting purity was >95% for each experiment. For T cell proliferation assays, 1 3 10 5 of naive CD4 + cells were cultured with or without immobilized anti-CD3 (2C11) and anti-CD28 for 48 h in 96-well microtiter plates. For antigenspecific T cell proliferation assays, APCs and naive CD4+ T cells from OT-II transgenic mice expressing T cell receptor (TCR) specific for ovalbumin (OVA) were co-incubated in the presence of OVA peptides for 48 h. Pre-activated T cells were prepared according to the following: splenocytes from OT-II mice were cultured with 1 lg ml À1 of OVA peptide as described above or isolated naive CD4 + T cells were incubated with anti-CD3 and anti-CD28 for 4 days. To measure cell proliferation, cells were pulsed with 2 lCi [ 3 H]thymidine ([ 3 H]TdR) for the last 12 h. Levels of cytokines in the culture supernatants were measured using Bio-Plex suspension array system (Bio-Rad, Hercules, CA, USA).
In vitro T cell priming
Mice were immunized with 10 lg keyhole limpet hemocyanin (KLH) in CFA in the hind footpads. Anti-TIM-4 (100 lg per mouse per day) or rat IgG was injected for 3 days after immunization. Five days after priming, draining LNs were harvested and 1 3 10 5 cells were stimulated for 48 h with various concentrations of KLH in the presence of irradiated splenocytes (5 3 10 5 ) in 96-well microtiter plates. Cells were pulsed with 2 lCi of [ 3 H]TdR for the last 12 h. Cytokine levels in the culture supernatants were measured using BioPlex as described above.
Cell cycle analysis
Immunofluorescence staining of incorporated bromodeoxyuridine (BrdU) and 7-amino-actinomycin D (7-AAD) were performed to identify the cells that are actively synthesizing DNA (by BrdU incorporation) in terms of their cell cycle position (defined by 7-AAD staining intensities) (BD PharMingen). Briefly, CD4
+ T cells were incubated on the plate coated with anti-CD3 (5 lg ml À1 ) plus human IgG1 or TIM-4-Fc (20 lg ml À1 ) in the presence of 10 lM BrdU for 48 h. Cells were fixed and permeabilized, treated with DNase to expose BrdU epitopes, and then stained with allophycocyanin-conjugated anti-BrdU and 7-AAD. Cells were analyzed by flow cytometry.
Immunoblot analysis
Naive CD4
+ T cells (5 3 10 6 ) or pre-activated T cells were lysed in buffer containing 1% Triton X-100, 150 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1 mM Na 3 VO 4 , 0.5 mM phenylmethylsulfonylfluoride, 1 lg ml À1 aprotinin, 1 lg ml À1 leupeptin and protease inhibitors. The protein concentrations of the lysates were determined using a bicinchoninic acid assay (Pierce Biotechnology, Rockford, IL, USA). Twenty micrograms of each sample was subjected to SDS-PAGE and electrophoretic transfer to nitrocellulose membranes. Membranes were immunoblotted with phospho-LAT (Tyr171, #3581), phospho-Erk1/2 (Thr202/Tyr204, #9101), phospho-p70 S6 kinase (Thr421/Ser424, #9204) or total Erk1/2 (#9102) antibodies from Cell Signaling Technology (Beverly, MA, USA) or anti-cdk4, anti-cdk6 or antip27 antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The bound antibodies were detected by appropriate HRP-conjugated secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA) and developed by chemiluminescence (enhanced chemiluminescence, GE Healthcare).
Induction of contact hypersensitivity
BALB/cA mice were painted with 30 ll of 0.5% 2,4-dinitrofluorobenzene (DNFB) (Sigma, St Louis, MO, USA) in acetone/olive oil (4:1) on their shaved abdomens on days 0 and 1. On day 5, the left ear was challenged with 0.2% DNFB and the right ear was treated with vehicle (10 ll of each side). Ear thickness was measured using a springloaded caliper (Mitutoyo, Kawasaki, Japan). For adoptive transfer, donor mice were sensitized with DNFB as described above, and then T cells were isolated from draining LNs by negative selection using T cell enrichment columns (R&D Systems, Minneapolis, MN, USA). Cells (1 3 10 7 ) were injected into recipient mice and immediately treated with 0.2% DNFB solution on the left ear. To examine T cell recruitment, DNFB-sensitized T cells were labeled with 1 lM carboxyfluorescein diacetate, succinimidyl ester (CFDA SE; CFSE, Molecular Probes, Eugene, OR, USA), and 5 3 10 6 cells were injected following treatment with DNFB as described above. Twelve hours after transfer, the dorsal portions of the ear dermis were collected and single-cell suspensions were prepared as previously described (12) . CFSE-positive cells from a total of 5 3 10 5 nucleated cells were enumerated by flow cytometry.
Induction of experimental autoimmune encephalomyelitis
On day 0, C57BL/6J mice were injected subcutaneously with the 5 lg ml À1 of myelin oligodendrocyte glycoprotein (MOG) 35-55 peptide (Sigma) emulsified in CFA (Sigma). The mice received intravenously 100 ng of pertussis toxin (List Laboratories, Campbell, CA, USA) on days 0 and 2. Control rat IgG or anti-TIM-4 was injected for indicated period with 100 lg per mice. The clinical signs of experimental autoimmune encephalomyelitis (EAE) were scored as previously described (13) . For EAE induction in the adoptive transfer model, donor mice were immunized with MOG-CFA in the same fashion as when inducing EAE, but no pertussis toxin was administered. Spleens and draining LNs were collected 10 days later, and single-cell suspension was prepared and RBCs were lysed. Cells were cultured for 3 days in RPMI 1640 medium with 30 lg ml À1 of MOG 35-55 peptide and with 10 ng ml À1 of recombinant mouse IL-12 (R&D Systems). Cells were harvested and T cells were isolated by negative selection using T cell enrichment columns (R&D Systems). Recipient mice were irradiated sub-lethally (500 cGy) and intravenously received 
Statistical analysis
To analyze statistical significance, we used an unpaired, two-tailed Student's t-test, unless specified otherwise. We considered P values <0.05 to be significant.
Results
Generation and characterization of anti-TIM-4 antibodies
We generated two mAbs specific for TIM-4 by immunizing rats with recombinant soluble TIM-4 (fused with the Fc portion of human IgG1, TIM-4-Fc) and by screening the hybridomas for reactivity with 2B4 cell transfectants expressing TIM-4. One mAb (1F6, rat IgG1, j) specifically bounds to TIM-4-expressing 2B4 cells but not to parent cells or to cells expressing TIM-1, TIM-2 or TIM-3 (Fig. 1a) . However, the 1F6 mAb could not inhibit the binding of TIM-4-Fc to TIM-1-expressing cells. The second TIM-4 mAb (4H12, rat IgG1, k) could block the binding of TIM-4-Fc to TIM-1 but showed cross-reactivity to TIM-1 ( Fig. 1a and b) . As a recent report showed that an anti-TIM-1 mAb can activate T cells in vitro and in vivo (7, 14) , We examined the cross-reactivity of 4H12 mAb to naive and activated CD4 + T cells. Unexpectedly, 4H12 mAb binds to neither naive nor activated CD4 + T cells even though activated T cells express TIM-1 (Fig. 1c) . On the other hand, TIM-4 on primary DCs was detectable similarly by both 4H12 and 1F6 (data not shown), suggesting that 4H12 could cross-react with a unique epitope of TIM-1 expressed on 2B4 cells which may not be seen in primary cells. We also confirmed that the 4H12 antibody did not affect T cell proliferation, stimulate APCs in vitro or induce the depletion of APCs in vivo (data not shown). These results indicate that 1F6 is a TIM-4-specific but a non-functional antibody and 4H12 is a functional, blocking antibody. In the following experiments, 1F6 was employed for flow cytometry and immunohistochemical studies and 4H12 was used for functional studies.
TIM-4 expression is restricted on macrophages and DCs and is inducible after stimulation in vivo
Flow cytometry of splenocytes with the 1F6 mAb revealed surface expression of TIM-4 on CD11b + macrophages and CD11c high DCs but not on resting or activated CD4 + T, CD8
+ T or B220 + B cells (Fig. 2a) . TIM-4 expression was observed on CD11c high DCs regardless of CD4 + or CD8a + DCs and was much weaker in B220 + CD11c int plasmacytoid DCs. Immunohistochemistry of spleen sections showed that the TIM-4-positive cells were localized in the T cell zone and in the marginal zone. As reported previously, MOMA-1 + I-A + marginal metallophilic macrophages highly expressed TIM-4 ( Fig. 2a and b) . TIM-4-positive cells were also stained with CD11c; however, the staining patterns were not completely concordant, possibly due to the lower TIM-4 expression on DCs than on metallophilic macrophages. To test whether activation of DCs induced higher expression of TIM-4, splenic CD11c + cells were stimulated in vitro by LPS or anti-CD40. Neither LPS nor anti-CD40 enhanced the expression of TIM-4 (Fig. 2c) . However, TIM-4 expression was 3-to 4-fold higher on DCs migrating to draining LNs after stimulation by contact sensitizer and on DCs that phagocytosed Escherichia coli particles compared with the DCs from LNs in unstimulated mice (Fig. 2d and e) . These immigrant DCs expressed higher levels of MHC class II than did LN-resident DCs (data not shown), indicating that the expression of TIM-4 could be enhanced after stimulation of sensitizers or phagocytosis of bacteria.
TIM-4 binds to naive CD4
+ T cells that do not express TIM-1 
CD44
low naive T cells in which TIM-1 was not expressed (Fig. 3a) . To test the TIM-4-binding specificity to naive and activated CD4 + T cells, TIM-1-Fc was co-incubated with TIM-4-Fc and TIM-4-binding activity was analyzed. TIM-1-Fc did not inhibit TIM-4 binding to naive T cells but partially inhibited to activated T cells (Fig. 3a) , suggesting that TIM-4-binding epitope of the ligand on naive T cell could be different from those of TIM-1. Reverse transcription-PCR showed that naive CD4
+ T cells do not express TIM-1 mRNA in contrast to its high expression on activated CD4 + T cells (Fig. 3b ). These findings indicate that a TIM-4-binding molecule other than TIM-1 could be expressed on naive T cells.
TIM-4 inhibits naive CD4 + T cell proliferation
To test whether TIM-4 has any effect on T cell activation, naive CD4 + T cells were stimulated with immobilized anti-CD3 and soluble anti-CD28 in the presence of TIM-4-Fc or control human IgG1. As shown in Fig. 4(a) , TIM-4-Fc significantly inhibited T cell proliferation. The 4H12 antibody not only blocked TIM-4-Fc binding to naive and activated CD4 + T cells (Fig. 4b) but also abolished the inhibitory effect of TIM-4-Fc (Fig. 4a) . In addition to TIM-4-Fc protein, membrane-bound TIM-4 appears to have an inhibitory role because the proliferation of naive CD4 + T cells was still significantly decreased in the presence of TIM-4-expressing cells (Fig. 4c) . Although it has been reported that low doses of TIM-4-Fc inhibited T cell proliferation but high doses of TIM-4-Fc enhanced proliferation, our findings showed that at least for naive T cells, both proliferation and IL-2 production were decreased by TIM-4-Fc in a dose-dependent manner (Fig. 4d) . Furthermore, TIM-4-Fc inhibited proliferation regardless of the concentration of anti-CD3 and anti-CD28 (Fig. 4d) . To determine the kinetics of the requirement for TIM-4 to exert its inhibitory activity, naive T cells were stimulated with anti-CD3, and TIM-4-Fc was subsequently added after 12 or 24 h. Interestingly, the inhibitory effect on proliferation of T cells was diminished after 12 h of activation and T cells that had been activated for 24 h could not be inhibited by TIM-4-Fc (Fig. 4e) . To examine the precise function of TIM-4 in APC-T cell interaction, we prepared mouse fibroblast-like cell lines expressing MHC class II molecules and CD80 (IC187 cells) for use as APCs. TIM-4-expressing IC187 cells were generated by retroviral vector-mediated gene introduction. The expression of both MHC class II and CD80 was unchanged by the induction of TIM-4 (data not shown). Mitomycin-C-treated control IC187 cells IC187 cells or IC187-TIM-4 cells were cultured with naive CD4 + T cells from OT-II transgenic mice that express an OVA-specific TCR, as well as with OVA peptide. Antigen-specific proliferation was significantly reduced when OT-II T cells were cultured with IC187-TIM-4 cells as compared with control IC187 cells (Fig.  4f) . However, T cells cultured with these APCs could produce cytokines equivalently (Fig. 4g) , indicating that TIM-4-expressing APCs did not induce anergy in T cells. To examine their ability to stimulate pre-activated T cells, splenocytes from OT-II mice were incubated with OVA peptide for 4 days, and then CD4 + T cells were isolated and rested overnight. The response of pre-activated OT-II CD4 + T cells against antigens presented by parent IC187 cells was comparable to that presented by IC187-TIM-4 cells (Fig. 4h) . IFN-c production was rather enhanced in T cells incubated with IC187-TIM-4 cells by re-stimulation with low doses of OVA (Fig. 4i) . These findings indicate that the inhibitory properties of TIM-4 are specific for naive T cells and not for activated T cells.
TIM-4 down-regulates the ERK kinase pathway in naive T cells but not in activated T cells
We then analyzed the effects of TIM-4-Fc treatment on TCR signals including the phosphorylation of various adaptor and kinase molecules. The phosphorylation of linker for activation of T cells (LAT) and extracellular-signal-regulated kinase 1/2 (ERK1/2) stimulated by anti-CD3 and anti-CD28 was reduced by TIM-4-Fc treatment in naive T cells. These results demonstrate that TIM-4-TIM-4 ligand interaction affects TCR signals (Fig. 5a ). The p70 S6 kinase (p70 S6K) is a downstream target of ERK and is required for cell growth and proliferation. We found that the phosphorylation of p70 S6K was also decreased in TIM-4-treated T cells (Fig. 5a ), suggesting at least one mechanism for the anti-proliferative property of TIM-4. On the other hand, phosphorylation of LAT, ERK1/2 and p70 S6K in TIM-4-treated pre-activated T cells was comparable to control cells, indicating that TIM-4 does not interfere with signal transduction in activated T cells.
TIM-4 induces cell growth arrest by suppressing cell cycle regulator proteins
As the activation of p70 S6K is essential for cell cycle progression (15), it is possible that TIM-4-Fc treatment may influence the cell cycle in stimulated T cells. To test this possibility, naive CD4 + T cells were stimulated by immobilized anti-CD3 and anti-CD28 with 10 lM of BrdU in the presence or absence of TIM-4-Fc for 48 h. The cell cycle phase and active DNA synthetic activity of cells were determined by flow cytometry after staining with 7-AAD and anti-BrdU. These staining conditions allowed for the discrimination of cell subsets that were apoptotic (defined as sub-G0/G1) or resided in G0/G1, S or G2/M phases (16) . We found that TIM-4-Fctreated T cells did not undergo apoptosis but had significantly impaired cell cycle progression to S phase (Fig. 5b) . We also found that TIM-4 treatment did not affect the number of T cells stained with Annexin-V (data not shown). Although cell growth was arrested almost completely, CD69 expression was observed on 48.8% of TIM-4-treated T cells. Cell cycle progression is regulated by cyclins, cyclin-dependent kinases (CDKs) and CDK inhibitors (17) . CDK2 and CDK4 are cell cycle control proteins required for G1/S phase transition and p27 kip1 inhibits their activity (18) . Stimulation of T cells by anti-CD3 induced CDK2 and CDK4 as well as the degradation of p27 kip1 , whereas TIM-4-treated T cells showed severe reductions in CDK2, CDK4 and degraded p27 kip1 (Fig. 5c ). These findings indicate that TIM-4 treatment induces G0/G1 cell growth arrest during the activation of naive T cells.
Blocking of TIM-4 enhances the initial phase of immune responses
To evaluate the physiological role of TIM-4 in T cell activation, we carried out in vitro and in vivo experiments using anti-TIM-4-blocking antibody (clone 4H12). OT-II naive CD4 + T cells were cultured with OVA peptides and CD11c + splenic DCs. T cell proliferation was increased in the presence of anti-TIM-4 at lower peptide concentrations (10 and 100 ng ml
À1
), but these effects were not apparent at a higher peptide concentration (1.0 lg ml À1 ) (Fig. 6a) . To further test the involvement of TIM-4 in antigen-mediated T cell activation in vivo, we subcutaneously immunized mice with KLH in CFA and then intravenously injected anti-TIM-4 for 4 days. Six days after immunization, CD4 + T cells were prepared from draining LNs and tested in vitro for antigen-specific responses. CD4 + T cell responses to KLH were markedly enhanced in anti-TIM-4-treated mice compared with control rat IgG-treated mice (Fig. 6b) . In addition, serum KLH-specific IgM levels were also increased in anti-Tim-4-treated mice (Fig. 6c) . Collectively, these findings suggest that TIM-4 plays an inhibitory role in the development of antigen-specific T cells in vivo.
The effect of anti-TIM-4 treatment during the induction of contact hypersensitivity
We investigated the effect of blocking TIM-4 binding during T cell-mediated immune responses using contact hypersensitivity (CHS) model. Mice were sensitized with DNFB and + T cells were re-stimulated with the indicated IC187 cells plus OVA peptides and cytokine in the culture supernatant were measured. All error bars represent means 6 SDs of triplicate experiments. To measure cell proliferation, cells were pulsed with 2 lCi of [ then challenged with DNFB 5 days later to induce delayedtype hypersensitivity in the ears. Treatment with either three doses of anti-TIM-4 every day from day 0 or a single dose on day 5 resulted in a significant reduction in ear swelling (Fig. 7a) . The administration of a single dose on the day of re-challenge was sufficient to reduce the ear swelling. Histological examinations demonstrated a significant reduction of ear swelling and infiltration of mononuclear cell in the ear dermis in mice treated with anti-TIM-4 (Fig. 7c) . We then examined the effects of anti-TIM-4 during T cell priming. Five days after mice were sensitized with DNFB and treated with rat IgG or anti-TIM-4, T cells were isolated from draining LNs and stimulated with dinitrobenzene sulfonate (a watersoluble analog of DNFB) presented by syngeneic splenocytes. T cells from mice treated with anti-TIM-4 showed enhanced proliferation as compared with T cells from control mice (Fig. 7b) , which was consistent with the effect of anti-TIM-4 on T cells primed with protein antigen (Fig. 6b ). Next, we tested the effects of anti-TIM-4 in the effector phase of CHS. T cells from DNFB-sensitized mice were transferred into wild-type recipients and either control antibody or anti-TIM-4 was injected just before challenge with DNFB. Recipients pre-loaded with anti-TIM-4 showed reduced CHS responses compared with control animals, whereas recipients that received T cells from mice treated with anti-TIM-4 during the sensitization phase showed relatively enhanced ear swelling (Fig. 7d) . We also examined the effects of anti-TIM-4 on the recruitment of effector T cells into inflamed skin.
T cells from DNFB-sensitized mice were labeled with CFSE and injected intravenously into control antibody-or anti-TIM-4-treated recipient mice. As a result, T cells were effectively recruited into DNFB-treated ears but not into vehicle-treated ears and no difference was observed in T cell recruitment between control antibody-and anti-TIM-4-injected mice (Fig. 7e) . These results suggest that TIM-4 is not necessary for T cell trafficking to inflamed sites but is involved in the elicitation phase of hypersensitivity.
Administration of anti-TIM-4 in the induction of EAE
We next examined the effect of administration of anti-TIM-4 in EAE model. Mice were immunized with encephalitogenic MOG 35-55 peptide in CFA and were treated with six doses of anti-TIM-4 or rat IgG. The day of onset of disease was similar in both groups on days 12-14, whereas treatment with anti-TIM-4 resulted in the amelioration of clinical symptom (Fig. 8a) . However, T cell priming was enhanced by anti-TIM-4 administration, such as increased production of IFN-c and IL-17 in draining LNs (Fig. 8b) . To test the effect of anti-TIM-4 in the induction of EAE by MOG-specific T cells, anti-TIM-4 was injected in mice transferred with MOG-primed T cells. As a result, the clinical features of EAE resolved completely by the administration of anti-TIM-4 (Fig.  8c) . These findings were parallel to those of CHS experiments. Collectively, it is indicated that TIM-4 has a critical role in the induction of inflammatory responses. 
Discussion
It was shown previously that TIM-4 specifically binds to TIM-1, which is a potent co-stimulatory receptor on activated T cells (9) . However, our present study showed that TIM-4-Fc could also bind and exert a biological activity on naive T cells that did not express TIM-1.This observation indicates that TIM-4 has multiple binding partners. Considering that TIM-2, another member of the TIM family, binds not only to Sema4A (19) but also to ferritin (20) , this is not surprising although a molecular identification of the second TIM-4 receptor remains unknown. It is noteworthy that, unlike other TIM members, TIM-4 contains an arginine-glycine-aspartic acid triplet (RGD) in its IgV domain. Many integrin molecules bind to ligands using a recognition site that contains an RGD motif (21) . However, mutant TIM-4 with amino acid substitution at the RGD motif could still affect the activation of T cells (data not shown), excluding the possibility that RGD-binding integrins are candidates for the TIM-4-binding partner other than TIM-1.
TIM-4 inhibits activation of naive Tcells but not of pre-activated T cells, although it can bind to both types of T cells. This inhibitory effect appears to be mediated by a non-TIM-1 receptors because TIM-1 is not detectable in naive T cells at the protein or mRNA levels. TIM-1, a counter-ligand for TIM-4, is induced on activated T cells and TIM-1 engagement by TIM-4 is thought to provide co-stimulatory signals for T cells. Indeed, a previous report showed that TIM-4-Fc could stimulate T cell proliferation under certain conditions (9) . However, we could not obtain clear evidence for the stimulatory activity of TIM-4 on either naive or pre-activated T cells, except that TIM-4-expressing IC187 cells substantially enhanced cytokine production of pre-activated T cells in the presence of a low dose of antigen. Although we do not have a precise explanation for our failure to see an effect of TIM-4 on pre-activated T cells, one possibility is that preactivated T cells may express both TIM-1 and non-TIM-1 receptors and their signals counteract each other. (PD-1) and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) are known inhibitory receptors that are necessary for T cell anergy and tolerance (22, 23) . These inhibitory receptors are inducible on activated T cells and play roles at the late phase of T cell activation and at the effector phase of immune responses. On the other hand, the expression of TIM-4 is increased on mature DCs, while the non-TIM-1 receptor is constitutively expressed on naive T cells. The inhibitory effect of TIM-4 is specific for naive T cells and, notably, TIM-4-Fc does not inhibit the proliferation of or the cell cycle progression of T cells pre-activated for 24 h, despite the increased binding of TIM-4-Fc to these cells. This indicates that the inhibitory effect of naive T cell activation by TIM-4, accompanied by reduced TCR signals, is exerted at the very early phase of T cell responses where T cells do not express TIM-1. Moreover, the TIM-4 signal via the non-TIM-1 receptor does not induce anergy in T cells. These actions are quite different from those of co-inhibitory molecules such as PD-1 and CTLA-4. Therefore, TIM-4 exerts its inhibitory role at the initial phase of the immune response and might be involved in regulating the magnitude of early activation of naive T cells by modulating the threshold of TCR signal activation.
Our in vivo experiments using a mouse CHS model demonstrate the bimodal effects of anti-TIM-4 mAb on T cell immunity. In vivo administration of anti-TIM-4 mAb enhanced the generation of hapten-specific effector T cells. Although this observation is in good agreement with an inhibitory activity of TIM-4, the cross-reactivity of our anti-TIM-4 (4H12) with TIM-1 raises the possibility that this mAb may directly enhance activation of T cells by binding to TIM-1. Indeed, some of anti-TIM-1 mAbs have been shown to exert agonistic or antagonistic effect on T cell activation (11, 14) . However, the 4H12 antibody failed to stimulate or inhibit proliferation of anti-CD3-stimulated T cells. Therefore, it is likely that the enhanced priming of hapten-specific T cells in anti-TIM-4-treated mice is due to a blockade of the inhibitory activity of endogenous TIM-4 expressed on DCs during their interaction with T cells.
Interestingly, anti-TIM-4 treatment significantly suppressed clinical symptoms and inflammation of hapten-challenged mice despite its enhancing effect on the generation of haptenspecific effector T cells. These paradoxical results could be explained by a distinct action of TIM-4 in the primary immune responses and in the initiation of inflammatory responses. Several lines of evidence suggest that TIM-4 could exert a stimulatory activity at the elicitation phase of CHS. (i) Delayed administration of anti-TIM-4 more effectively inhibited CHS; (ii) T cells from hapten-sensitized and anti-TIM-4-treated mice effectively developed CHS in recipient mice; (iii) the administration of anti-TIM-4 into recipient mice suppressed the development of CHS by T cells from sensitized donor mice and (iv) anti-TIM-4 treatment did not affect the trafficking of hapten-specific effector cells to the site of hapten challenge. At present, the precise mechanism of how TIM-4 is involved in the elicitation phase of CHS is unknown. However, it has been previously reported that a high dose of TIM-4-Fc can enhance T cell activation. Our in vitro data also show that TIM-4-expressing APCs enhance cytokine production of pre-activated T cells. Likewise, the administration of anti-TIM-4 also inhibited the induction of EAE. Notably, treatment with anti-TIM-4 completely blocked the development of EAE in mice transferred with encephalitogenic T celis, indicating an important role of TIM-4 in the T cell-mediated inflammation. Thus, TIM-4 expressed on APCs in the inflammatory site may play a stimulatory role in the reactivation of effector T cells. As activated T cells as well as effector T cells express TIM-1, TIM-4 may mediate such a stimulatory activity of TIM-1. Furthermore, a previous report shows that the administration of soluble TIM-1 reduces CHS and antigen-induced arthritis. It may be possible that soluble TIM-1 could block TIM-4-TIM-1 binding in APC-T cell interaction, leading to the reduction of effector phase of immune responses (24) . Further investigations are necessary to determine whether TIM-1 is involved in the effector phase of cellular immunity as a receptor for TIM-4.
In conclusion, we found that TIM-4 inhibits naive T cell activation through a non-TIM-1 receptor. On the other hand, blocking TIM-4 binding reduced the effector phase of immune responses. Thus, we propose that TIM-4 might have two different functions depending on the activation status of T cells: the negative regulation of naive T cells and the positive regulation of activated T cells. These findings imply that TIM-4 receptor blocking could be a potential therapeutic modality to manipulate the immune responses in a large number of diseases. 
